Semaglutida Berberina

Tirzepatide vs Semaglutide: Which GLP-1 Medication Is Better for Weight Loss?

Both tirzepatide and semaglutide are FDA-approved GLP-1 receptor agonists that have shown remarkable results for weight management. But which one is right for you? Here is a comprehensive comparison based on clinical trial data.

How They Work

Semaglutide (brand names: Ozempic, Wegovy) is a single GLP-1 receptor agonist. It mimics the incretin hormone to reduce appetite and slow gastric emptying.

Tirzepatide (brand names: Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist, targeting two metabolic pathways simultaneously for potentially greater efficacy.

Weight Loss Results

The STEP trials (semaglutide) showed an average weight loss of 15-17% of body weight over 68 weeks at the 2.4mg dose.

The SURMOUNT trials (tirzepatide) demonstrated even greater results, with an average weight loss of 20-26% of body weight over 72 weeks at the 15mg dose.

Which Should You Choose?

The choice between semaglutide and tirzepatide depends on your individual health profile, insurance coverage, and treatment goals. Consult with your healthcare provider to determine the best option for you.

For a detailed side-by-side comparison including dosing protocols, side effects, costs, and clinical data, read our complete tirzepatide vs semaglutide comparison guide.

Quality GLP-1 medications with full Certificate of Analysis are available at Glunova Biotech.